Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Harvard Bioscience Q2 Adj. EPS $(0.01), Inline, Sales $20.45M Beat $20.40M Estimate

Author: Benzinga Newsdesk | August 11, 2025 07:07am
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. The company reported quarterly sales of $20.45 million which beat the analyst consensus estimate of $20.40 million by 0.25 percent. This is a 11.46 percent decrease over sales of $23.10 million the same period last year.

Posted In: HBIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist